The main objective of the present work was the development of new nanoparticulate carrier systems for the delivery of plasmid DNA. These new carriers consist of a blend matrix formed by a poly(lactic-co-glycolic acid) (PLGA) copolymer and polyoxyethylene derivatives. More specifically, we have prepared nanostructures with different PLGA:poloxamer and PLGA:poloxamine compositions by an optimized emulsification-solvent diffusion technique and studied the potential of these carriers for the encapsulation and controlled release of plasmid DNA. Depending on the particle composition, the encapsulation efficiency of the model plasmid pEGFP-C1 varied between 30% and 45%. All formulations provided continuous and controlled release of the plasmid with minimal burst effect. In addition, the release rate and duration was dependent on the composition of the particle matrix. Moreover, gel electrophoresis and cell culture (MCF-7 cell line) assays allowed us to confirm that the biologically active form of the plasmid was preserved during the particle preparation process and also during its release. Cell culture experiments also indicated that the new nanoparticles do not exhibit toxic effects on these cells at concentrations up to 5 mg/mL. Altogether, these results indicate that these composite nanostructures present a promising approach for the delivery of plasmid DNA.
The aim of the present work was the design of novel nanoparticle compositions based on poly(lactic acid/glycolic acid) (PLGA): poloxamer and PLGA: poloxamine blend matrices. For this purpose, we have applied a modified solvent diffusion technique that allows the preparation of the nanoparticles without the use of high energy sources. Nanoparticles have been prepared with different PLGA: poloxamer and PLGA: poloxamine ratios using PEO-derivatives with different molecular weights (Mw) and hydrophilia-lipophilia balance (HLB) values. Our results show that the physicochemical characteristics of the nanoparticles, such as size and zeta potential, are influenced by the type of PEO-derivative associated to the PLGA matrix. The 1H-NMR analysis of the different nanoparticle compositions showed that the extent of incorporation of the PEO-derivative depends strongly on its HLB and also on the nanoparticles preparation conditions. The capacity of these nanoparticles as drug delivery devices was evaluated using bovine insulin as a model drug. The insulin-encapsulation efficiency was shown to be dependent on the composition of the nanoparticles, those containing hydrophilic PEO-derivatives being the most effective in entrapping the drug molecules. The formation of the blend system displayed positive effects on the release characteristics of the nanoparticles. Nanoparticles exhibited a reduced initial burst and a nearly linear, constant release rate over a time period of two weeks.
Poly(lactide-co-glycolide) (PLGA) microparticles (MP) possess immunological adjuvant properties. Yet, exploitation of their full potential has just begun. The purpose of this study was to explore opportunities arising from surface modifications, and attachment and entrapment of combinations of antigen and a Toll-like receptor (TLR) ligand. The cytotoxic T lymphocyte (CTL)-restricted OVA ovalbumin peptide SIINFEKL was microencapsulated into bare, chitosan-coated, and protamine-coated PLGA MP using a microextrusion-assisted solvent extraction process. A TLR-ligand (CpG ODN) was either covalently coupled or physically adsorbed onto the MP surface. The peptide encapsulation efficiency decreased from 71% for uncoated particles to 62% and 45% upon coating with chitosan and protamine, respectively. CpG adsorption efficiency decreased from 93% for protamine-coated particles to 19% and 8% for chitosan and bare particles. Release of the adsorbed CpG was slow and incomplete (23% within 7 days) with the protamine coating, intermediate (>90% within 3 days) with the chitosan coating, and immediate (100% within 3 h) without coating. Interestingly, only the uncoated PLGA MP with adsorbed CpG mediated a prominent CTL response in mice at 6 days after immunization, as determined from IFN-gamma release from antigen-specific CD8+ cells; failure of the other MP formulations was ascribed to the low release of antigen and CpG within the first week after immunization. The study illustrates novel opportunities for PLGA MP vaccines by combining antigens and immunostimulatory ligands.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.